Abbott Laboratories (ABT) Buys AP214 Hormone From Action Pharma for $110 Million
5/3/2012 10:49:10 AM
More...
|
Action Pharma's Phase 2b Clinical Trial with AP214 to Prevent Kidney Injury Associated with Major Cardiac Surgery Demonstrates Positive Top-Line Results
9/26/2011 8:00:19 AM
More...
|
Action Pharma Completes Last Patient Last Visit in Phase IIb Trial with AP214
8/8/2011 10:46:38 AM
More...
|
Action Pharma Completes Dosing in Phase IIb Clinical Trial with AP214 to Prevent Acute Kidney Injury Associated with Cardiac Surgery
5/9/2011 9:50:52 AM
More...
|
Action Pharma Initiates Phase IIb Clinical Trial in the USA And Denmark With AP214 to Prevent Kidney Injury Associated With Major Cardiac Surgery
11/8/2010 1:26:42 PM
More...
|
Action Pharma Obtains Positive Results in A Phase II Clinical Trial With AP214 to Prevent Acute Kidney Injury Associated With Cardiac Surgery
9/13/2010 3:51:54 PM
More...
|
Action Pharma Raises Eur 5 Million
6/9/2010 7:25:56 AM
More...
|
Action Pharma Obtains Encouraging Preliminary Results In A Phase II Clinical Trial With AP214
6/7/2010 12:30:10 PM
More...
|
Action Pharma Completes EUR 5 Million (6.1Million USD) Financing Round To Advance Its Lead Project AP214
6/3/2010 11:40:38 AM
More...
|
Action Pharma Focuses Its Strategy And Appoints Ingelise Saunders As New CEO
3/24/2010 11:31:16 AM
More...
|
|